iTeos Therapeutics to Participate in Upcoming September Investor Conferences

iTeos Therapeutics, a clinical-stage biopharmaceutical company, announced participation in five virtual investor conferences throughout September 2021.

Rhea-AI Summary

iTeos Therapeutics, a clinical-stage biopharmaceutical company, announced participation in five virtual investor conferences throughout September 2021. Key events include the KBC Securities Life Sciences Conference on September 7 and the Wells Fargo Virtual Healthcare Conference on September 9-10. Additionally, iTeos will present at the Morgan Stanley 19th Annual Global Healthcare Conference from September 9-15, the H.C. Wainwright Annual Global Investment Conference on September 13, and the Cantor Fitzgerald Global Healthcare Conference on September 27. Audio webcasts will be accessible on their website.

Argus Session date unavailable

+0.81% session move Open Argus

Details

News Market Reaction – ITOS

The recorded move for ITOS in the trading session of this news was +0.81%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass. and GOSSELIES, Belgium, Sept. 01, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immune-oncology therapeutics for patients, today announced that company management will participate in five upcoming virtual investor conferences in September:

• KBC Securities Life Sciences Conference
  Format: Management one-on-ones
  Date: September 7, 2021

• Wells Fargo Virtual Healthcare Conference
  Format: Management one-on-ones
  Date: September 9-10, 2021

• Morgan Stanley 19^th Annual Global Healthcare Conference
  Format: Management one-on-ones
  Date: September 9-10 and 13-15, 2021

• H.C. Wainwright 23^rd Annual Global Investment Conference
  Format: On demand presentation by Michel Detheux, Ph.D., President and Chief Executive Officer
  Date/Time: Monday, September 13, 2021 at 7:00 a.m. ET

• Cantor Fitzgerald Global Healthcare Conference
  Format: Live presentation by Michel Detheux, Ph.D., President and Chief Executive Officer
  Date/Time: Monday, September 27, 2021 at 2:40 p.m. ET

Audio webcasts of the presentations will be available on the Investor section of the company’s website at https://www.iteostherapeutics.com. An archived replay will be available for approximately 30 days following the presentation.

About iTeos Therapeutics, Inc.
iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients. The Company’s innovative pipeline includes two clinical-stage programs targeting novel, validated immuno-oncology. The initial antibody product candidate, EOS-448, is a high affinity, potent, anti-TIGIT antibody with a functional Fc domain, designed to enhance the anti-tumor response through a multifaceted immune modulatory mechanism. An open-label Phase 1 clinical trial of EOS-448 is ongoing in adult cancer patients with advanced solid tumors with preliminary data indicating preliminary clinical activity as a monotherapy and a favorable tolerability profile. The Company is also advancing inupadenant, a first insurmountable adenosine A2A receptor antagonist in clinical development tailored to overcome cancer immunosuppression. iTeos is conducting an open-label multi-arm Phase 1/2a clinical trial of inupadenant in adult cancer patients with advanced solid tumors. Preliminary results indicate encouraging single-agent activity as well as the identification of a potential predictive biomarker. iTeos Therapeutics is headquartered in Cambridge, MA with a research center in Gosselies, Belgium.

For further information, please contact:

Investor Contact:
Ryan Baker
iTeos Therapeutics, Inc.
Ryan.Baker@iteostherapeutics.com

Media Contact:
media@iteostherapeutics.com

 

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is the schedule for iTeos Therapeutics investor conferences in September 2021?

iTeos Therapeutics will participate in five virtual investor conferences throughout September 2021, including the KBC Securities Life Sciences Conference on September 7 and the Wells Fargo Virtual Healthcare Conference on September 9-10.

Who is presenting at the H.C. Wainwright Global Investment Conference for ITOS?

Michel Detheux, Ph.D., President and CEO of iTeos Therapeutics, will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021.

When will audio webcasts be available for iTeos Therapeutics presentations?

Audio webcasts of iTeos Therapeutics presentations will be available on their Investor section for about 30 days after the events.

What product candidates are in development at iTeos Therapeutics?

iTeos Therapeutics is advancing EOS-448, an anti-TIGIT antibody, and inupadenant, an adenosine A2A receptor antagonist, both targeting advanced solid tumors.

How is iTeos Therapeutics addressing cancer immunosuppression?

iTeos Therapeutics is developing inupadenant, designed to overcome cancer immunosuppression, and is currently conducting a multi-arm Phase 1/2a clinical trial.